Introduction {#s001}
============

Brain-derived neurotrophic factor (BDNF) plays an important role in the development, regulation, and survival of neurons in the hippocampus, and other structures relevant to cognitive function.^[@B1]^ BDNF deficiency has been associated with neurocognitive disorders and metabolic diseases.^[@B2]^ Furthermore, BDNF is also associated with physical activity.^[@B6]^ Although the exact mechanism of action remains unknown, it has been hypothesized that BDNF could be one factor accounting for the beneficial effects of physical activity on neurocognitive function, by promoting cell growth and survival in the hippocampal neurons.^[@B6]^ In addition, interaction effects between genetics with physical activity and metabolic parameters have been reported.^[@B7]^ BDNF is implicated in the regulation of food intake and body weight, by suppressing food intake through hippocampal signaling and enhancing energy expenditure.^[@B5],[@B8],[@B9]^ Although the pathology of obesity is multifactorial, studies have reported an inverse association between lower BDNF serum concentration and higher body mass index (BMI) and percentage of body fat.^[@B10]^

The BDNF gene is located on chromosome 11p14.1. Considerable allele and haplotype diversity in the BDNF gene has been observed among different ethnic populations. It has been reported that there is a specific genetic variant within the gene that may influence the risk of obesity, Alzheimer\'s disease, cognitive impairment, and other health conditions.^[@B8],[@B13]^ There is a well-identified single nucleotide polymorphism (SNP) expressed in the pro-region of the BDNF gene on position 66 (change from valine to methionine): rs6265.^[@B14]^ This change results in aberrant sorting of BDNF into secretory vesicles and decreased activity-dependent secretion.^[@B14]^ The rs6265 variant is of particular interest, because it is the only known frequent nonconservative polymorphism in the BDNF gene^[@B12]^ and is associated with various health conditions, such as obesity and type 2 diabetes.^[@B12],[@B15],[@B18]^

To date, the majority of BDNF studies have been conducted in animal models.^[@B5],[@B9],[@B19],[@B20]^ The few published human studies predominantly involve Caucasian or Asian populations and reported conflicting results on the associations between health conditions, particularly obesity, and the rs6265 polymorphism.^[@B10],[@B12],[@B15],[@B18]^ The association of the rs6265 SNP and BMI has not been described among Latinos who are the fastest growing minority group in the United States.^[@B21]^ Latinos are disproportionately affected by obesity and have a high prevalence of chronic diseases such as diabetes and cardiovascular disease.^[@B22]^ According to the National Hispanic Council on Aging, Latinos engage in less physical activity than non-Hispanic whites, which may put them at higher risk for metabolic disorders.^[@B23],[@B24]^ Therefore, the aim of our study was to investigate the cross-sectional associations between the BDNF rs6265 polymorphism, physical activity, and BMI among a community-based sample of Latinos residing in Phoenix, Arizona. We hypothesized that higher serum BDNF levels would be associated with a higher level of physical activity and lower BMI. In addition, we hypothesized that there would be a higher frequency of the BDNF rs6265 mutation among participants who had lower serum BDNF levels and reported less physical activity.

Materials and Methods {#s002}
=====================

Study participants {#s003}
------------------

This study utilized existing stored biospecimens and previously collected data from participants enrolled in the Arizona Insulin Resistance Registry. In brief, individuals who identified themselves as Latino or Mexican American between the ages of 18 and 85 years were recruited through community clinics, flyers, and word of mouth.^[@B25]^ Participants completed a detailed medical history and an intake questionnaire. Engagement in physical activity was assessed through one item from the intake questionnaire: "Do you participate in exercise? Yes/No." If participants answered "yes," then further details were obtained regarding intensity, frequency, and duration. The physical examination included anthropometric measures (height, weight, and waist circumference), seated blood pressure, fasting laboratory measures (comprehensive metabolic and lipid panel), and an oral glucose tolerance test. In addition, participants provided consent to collect and bank fasting serum, DNA, and RNA for future use. All data were entered into a searchable REDCap database and biospecimens were stored at −80°C in individual aliquots at Arizona State University (ASU) laboratories, housed in the Mayo Clinic Arizona campus. The study was approved by the Institutional Review Board of Arizona State University. Written informed consent was obtained from each participant before participation.

Laboratory procedure {#s004}
--------------------

We used Mayo Clinic\'s Biospecimens Accessioning and Processing laboratory to process the BDNF assays. BDNF levels were measured in the serum, given that serum BDNF levels are reflective of brain BDNF.^[@B26]^ To analyze serum BDNF levels, we used a modified ELISA method.^[@B27]^ SNP genotyping for rs6265 was performed by the Assay-by-Design service (Applied Biosystems, CA.), as previously described.^[@B28]^ In brief, in a 384-well plate, 2 μL of purified genomic DNA (2 ng/μL) were incubated with primers and probes with the SNP of interest (0.09 μL), 3.5 μL of TaqMan Universal Polymerase Chain Reaction Master Mix-No AmpErase UNG, and 1.14 μL of distilled water. Samples were polymerase-chain-reaction-amplified on the Applied Biosystems 9700HT Thermal Cycler under the following conditions: denatured for 10 min at 95°C, denatured, annealed, and extended for 40 cycles of 15 s at 92°C and 1 min at 60°C. The 384-well microplates were scanned for fluorescence emission using a 7900HT sequence detector (Applied Biosystems), and alleles were scored using the allelic discrimination software Sequence Detection System v2.3 (Applied Biosystems).

Statistical analysis {#s005}
--------------------

Age, BMI, fasting glucose, 2-hr glucose, and serum BDNF levels of participants who reported physical activity versus those who did not report physical activity were compared using two-sample *t*-test. Gender and rs6265 SNP groups (*i.e.*, CC, CT, and TT) were compared between physically active and nonactive participants using chi-squared test. Additional statistical comparisons between groups (*i.e.*, between CC and CT+TT combined rs6265 genotype groups) were made by using the two-sample *t*-test or chi-squared test. The associations between BDNF and age, BMI, and glucose (fasting or 2-hr) were quantified by using the Pearson correlation coefficient. With 225 patients in the CC group, and 118 patients in the CT+TT group, we have 80% power to detect an effect size 0.32 or larger (small to medium effect size) in a continuous phenotype trait between the two groups, assuming a 0.05 two-sided significance level. Statistical testing was performed at the conventional two-tailed *α* = 0.05 using SAS software Version 9.3 (SAS Institute, Inc.).

Results {#s006}
=======

Data were available on 349 participants (233 women and 116 men) with a mean age of 42 years. Mean (±SD) BDNF levels did not differ (*P* = 0.89) between men (33 ± 16 ng/mL) and women (33 ± 17 ng/mL). There were 195 participants (56%) who reported engaging in regular physical activity (*i.e.*, "active group"). The active group had a significantly smaller proportion of women, and a lower mean BMI than the nonactive group. Mean BDNF levels did not differ significantly between the active and nonactive group (Δ = −1 ng/mL, 95% CI −4 to 3, *P* = 0.64). Information on rs6265 genotype was available for 343 participants. Two hundred twenty-five participants (64%) were CC homozygous for the functional variant, 109 (31%) were CT heterozygous, and 9 (3%) were TT homozygous for the mutation. The minor allele frequency in our population was 0.1851. There was no significant difference in rs6265 genotype frequency between the physically active and nonactive group. Adjusting for age, gender, BMI, fasting glucose, or 2-hr glucose did not alter the results ([Table 1](#T1){ref-type="table"}).

###### 

Demographics, Body Mass Index, Glucose, and Brain-Derived Neurotrophic Factor Levels; Stratified by Physical Activity Group

                             *Active*                                                                   
  -------------------------- ---------------------- ---------------------- ------------ --------------- ---------
  Women                      118 (61%)              115 (75%)              −14.2%       −23.9 to −4.5   0.005
  Age (years); mean (SD)     41.7 (8.3)             41.5 (9.4)             0.2 (8.8)    −1.7 to 2.1     0.82
  BMI (kg/m^2^); mean (SD)   29.5 (4.9)             31.9 (7.5)             −2.3 (6.2)   −3.6 to −1.0    \<0.001
  Glucose (mg/dL)                                                                                       
   Fasting; mean (SD)        96 (31)                99 (40)                −3 (34)      −10 to 4        0.41
   2-Hr; mean (SD)           140 (61) \[*N* 189\]   150 (70) \[*N* 150\]   −11 (65)     −25 to 3        0.13
  rs6265                                                                                                
   N                         193                    150                                                 0.46
   CC                        123 (64%)              102 (68%)                                            
   CT                        66 (34%)               43 (29%)                                             
   TT                        4 (2%)                 5 (3%)                                               
   BDNF (ng/mL); mean (SD)   33 (16)                34 (17)                −1 (16)      −4 to 3         0.64

Δ, difference in means between active and nonactive groups; BDNF, brain-derived neurotrophic factor serum level; BMI, body mass index; 95% CI, 95% confidence interval; CC, CC homozygotes; CT, CT heterozygotes; rs6265, rs6265 single nucleotide polymorphism; SD, standard deviation; TT, TT homozygotes.

Mean BDNF levels did not differ between the CC and CT genotypes. Similarly, there were no differences regarding any other demographic characteristics between CC and CT genotypes ([Table 2](#T2){ref-type="table"}). Higher BDNF levels were significantly associated with higher age (*r* = 0.11, *P* = 0.04) and higher 2-hr glucose level (*r* = 0.11, *P* = 0.04; [Fig. 1](#f1){ref-type="fig"}). In addition, there was a marginally significant association between higher BDNF levels and higher fasting glucose levels (*r* = 0.10, *P* = 0.07). BDNF level was not associated with BMI (*r* = −0.05, *P* = 0.36).

![Correlation between BDNF serum level (in ng/mL) and 2-hr glucose level (in mg/dL). BDNF, brain-derived neurotrophic factor.](fig-1){#f1}

###### 

Demographics, Body Mass Index, Glucose, and Brain-Derived Neurotrophic Factor Levels; Stratified by CC and CT+TT rs6265 Genotype Group

                             *CC*                   *CT+TT*                Δ            *95% CI*       P
  -------------------------- ---------------------- ---------------------- ------------ -------------- ------
  Women                      151 (67.1%)            77 (65.3%)             1.9%         −8.7 to 12.4   0.73
  Age (years); mean (SD)     41.3 (8.5)             42.4 (9.4)             −1.1 (8.8)   −3.1 to 0.9    0.26
  BMI (kg/m^2^); mean (SD)   30.5 (6.5)             30.7 (5.7)             −0.2 (6.2)   −1.6 to 1.2    0.80
  Obese (BMI ≥30)            101 (44.9%)            57 (48.3%)             −3.4%        −14.5 to 7.7   0.55
  Glucose (mg/dL)                                                                                      
   Fasting; mean (SD)        99 (35)                96 (33)                3 (34)       −5 to 11       0.46
   2-Hr; mean (SD)           146 (70) \[*N* 220\]   141 (56) \[*N* 113\]   5 (66)       −9 to 19       0.46
  Active                     123 (54.7%)            70 (59.3%)             −4.7%        −15.6 to 6.3   0.41
  BDNF (ng/mL); mean (SD)    34 (17)                32 (15)                1 (16)       −2 to 5        0.49

Δ, difference in means between CC homozygotes and CT heterozygotes.

Discussion {#s007}
==========

Building upon the growing body of research on BDNF and its implication among different populations, we sought to determine the cross-sectional association between BDNF serum levels with BMI, physical activity, and the rs6265 polymorphism in a convenience sample of Latinos residing in Phoenix, Arizona. We observed that physical activity and the rs6265 polymorphism did not have any significant association with BDNF serum concentrations. In addition, the rs6265 polymorphism was also not associated with BMI in our sample.

To date, we have not identified a study that examined the association between rs6265 BDNF polymorphism and physical activity or BMI among Latinos. Given that physical activity is associated with increased BDNF expression, primarily in the hippocampus,^[@B19],[@B29],[@B30]^ we hypothesized that a higher level of physical activity would be associated with higher BDNF concentrations. However, we did not observe a significant difference in BDNF levels between the physically active and nonactive group. This may in part be explained by the relatively high BMI of the participants (including those who reported physical activity), which was mostly at overweight or obese levels. This is relevant since BMI has been reported to be directly affected by secreted levels of BDNF, undermining any potential effect that physical activity could have on BDNF expression.^[@B5]^ Another possible explanation is that BDNF response is transient after acute exercise and does not have a lasting effect.^[@B31],[@B32]^ In our study we did not measure BDNF after an acute bout of exercise, rather we used a survey to acquire data on regular physical activity.^[@B33]^ This may explain the absence of difference in BDNF levels between the physically active and nonactive group in our study.

We also investigated the association between the rs6265 SNP and serum BDNF level among Latinos. The frequency and distribution of methionine carriers (CT and TT) in our sample is consistent with previous studies that report BDNF genotype distributions in primarily non-Hispanic white samples.^[@B34]^ In our study, mean BDNF levels did not vary between CC and CT genotypes. Similar studies conducted in Chinese and Indian^[@B35],[@B36]^ populations reported that BDNF levels are not affected by the rs6265 polymorphism, supporting our findings that BDNF levels may not vary by genotype status.

Furthermore, we did not observe an association between the rs6265 polymorphism and BMI in our study sample. There are conflicting results as to whether rs6265 genotype is associated with BMI across populations.^[@B12],[@B13],[@B15],[@B18]^ For example, investigators from Mexico found that the rs6265 polymorphism confers a lower risk for obesity.^[@B16]^ However, a study in a Boston Puerto Rican sample reported a gender-specific association, that is, CC men had twice the risk of being overweight, whereas CC women had a lower mean BMI.^[@B8]^ Whereas we did not observe any gender- or age-specific associations, which could in part be explained by the fact that our population was on average 10 years younger than the Puerto Rican sample.

Finally, we observed weak correlations between BDNF levels with glucose levels and age. BDNF has been reported to impact metabolism of peripheral organs,^[@B2]^ and as a result, BDNF may be elevated after glucose ingestion, possibly playing a role in body weight balance.^[@B11]^ As for the association with age, further research is needed to determine the cause of the relationship with BDNF, since independent age-related increase has been reported in only one study.^[@B37]^

There are other possible explanations for the discrepancies between this study\'s findings and previous reports. For example, lifestyle factors such as low physical activity and poor diet may contribute to high obesity rates among Latinos and may also interact with genetic effects. In addition, poor socioeconomic status and long working hours may make it more difficult to adhere to healthy lifestyles and diet. Furthermore, lack of education may be a risk factor for metabolic syndrome and other chronic diseases. Finally, genetic variability may be another explanation. As mentioned earlier, most studies have used European and Caucasian samples and distribution of genotypes and phenotypes may differ between populations.

Our findings should be interpreted within the context of strengths and limitations of this study. The strengths of our study include a relatively large, community-based, low socioeconomic sample of Latino participants residing in Arizona. The main limitation of this study is a lack of genetic markers that would have enabled us to provide information on the ancestry groups or genetic substructure of our nonhomogenous sample. Furthermore, we were not able to rule out potential bias that may stem from genetic admixture or population stratification. However, potential bias due to these factors may be of less relevance to our study since we are not reporting a positive finding. The cross-sectional design is one of the limitations of our study. Such a design does not indicate the direction of causality. In addition, physical activity was assessed using a survey that may be susceptible to recall bias.

In summary, in this cross-sectional study among Latinos residing in Phoenix, Arizona, serum BDNF levels were not significantly associated with physical activity, BMI, or the rs6265 polymorphism. The rs6265 polymorphism was not associated with a higher risk of obesity or lower circulating levels of BDNF. Thus, the rs6265 polymorphism may have a different impact in Latinos as compared with other previously studied populations. Future prospective studies in a larger sample of Latinos are needed to confirm this preliminary finding.
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